Upward Revision to Earnings Forecast for the Fiscal Year Ending March 2021 and Outlook for Higher Revenue and Profit
First written in FY2021-Q2. 1 of 3 entries say "Raised", first in FY2021-Q3. Latest entry: FY2021.
The whole theme swung hardest in 2024: 1 of 6 companies on the "Worse" side.
9 other companies' latest entry also says "Achieved".
- FY2021AchievedAnnual report
「Revenue increased by ¥16.9 billion, or 5.8%, year on year to ¥309.3 billion. Operating profit increased by ¥20.8 billion, or 26.9%, to ¥98.3 billion. Profit for the period attributable to owners of the parent increased by ¥15.7 billion, or 26.3%, to ¥75.4 billion.」
Against the fiscal 2021 forecast revised upward as of the third quarter, comprising revenue of ¥309.0 billion, operating profit of ¥94.0 billion and profit for the period attributable to owners of the parent of ¥74.0 billion, actual results came in at ¥309.3 billion, ¥98.3 billion and ¥75.4 billion, respectively, exceeding the forecast levels. - FY2021-Q3RaisedAnnual report
「We expect revenue from royalties and other sources to exceed the previous forecast despite the anticipated impact of the price revision implemented in April. Accordingly, we have raised our revenue forecast by ¥4.0 billion from the previous forecast to ¥309.0 billion. As a result, we forecast operating profit of ¥94.0 billion, up ¥7.0 billion from the previous forecast, and profit before tax of ¥95.5 billion, also up ¥7.0 billion. Following a review of tax expenses, we forecast profit for the period of ¥74.2 billion, up ¥9.0 billion, and profit for the period attributable to owners of the parent of ¥74.0 billion, also up ¥9.0 billion, from the previous forecast.」
The forecasts were revised upward from the previous earnings forecast to revenue of ¥309.0 billion, operating profit of ¥94.0 billion and profit for the period attributable to owners of the parent of ¥74.0 billion. - FY2021-Q2First statedAnnual report
「We expect revenue from royalties and other sources to fall below the previous forecast, while revenue from products, including Opdivo, has been trending above the previous forecast. Accordingly, we have raised our revenue forecast by ¥2.0 billion from the previous forecast to ¥305.0 billion. We plan to launch new products and obtain additional indications for several products in the second half, and will strengthen our information-provision activities. However, as we will continue to be affected by COVID-19, we forecast revenue of ¥67.0 billion, down ¥3.0 billion from the previous forecast. As a result, we forecast operating profit of ¥87.0 billion, up ¥7.0 billion from the previous forecast; profit before tax of ¥88.5 billion, up ¥6.5 billion; profit for the period of ¥65.2 billion, up ¥4.1 billion; and profit for the period attributable to owners of the parent of ¥65.0 billion, up ¥4.0 billion.」
After factoring in the impact of COVID-19, the revenue and profit forecasts for the fiscal year ending March 2021 were revised upward from the previous forecasts, based on upside in product revenue and the launch of new products and addition of indications in the second half.